CM Management LLC Has $2.24 Million Stake in Organon & Co. (NYSE:OGN)

CM Management LLC increased its holdings in shares of Organon & Co. (NYSE:OGN) by 50.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 150,000 shares of the company’s stock after buying an additional 50,000 shares during the period. Organon & Co. accounts for about 1.9% of CM Management LLC’s investment portfolio, making the stock its 20th biggest holding. CM Management LLC owned approximately 0.06% of Organon & Co. worth $2,238,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Pacer Advisors Inc. grew its holdings in Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after purchasing an additional 11,140,388 shares during the period. Geode Capital Management LLC increased its holdings in shares of Organon & Co. by 2.0% in the third quarter. Geode Capital Management LLC now owns 4,248,108 shares of the company’s stock worth $81,288,000 after acquiring an additional 82,220 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Organon & Co. by 0.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,333,703 shares of the company’s stock worth $49,739,000 after acquiring an additional 10,652 shares in the last quarter. Thompson Siegel & Walmsley LLC raised its position in shares of Organon & Co. by 6.4% during the third quarter. Thompson Siegel & Walmsley LLC now owns 2,262,379 shares of the company’s stock worth $43,279,000 after purchasing an additional 136,457 shares during the period. Finally, Private Management Group Inc. lifted its holdings in shares of Organon & Co. by 11.9% during the 4th quarter. Private Management Group Inc. now owns 2,119,288 shares of the company’s stock valued at $31,620,000 after purchasing an additional 225,420 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on OGN shares. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Morgan Stanley dropped their price target on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. Finally, Barclays dropped their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.80.

Organon & Co. Stock Up 3.9 %

NYSE:OGN opened at $15.44 on Friday. The firm has a market capitalization of $3.98 billion, a price-to-earnings ratio of 4.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a twelve month low of $13.87 and a twelve month high of $23.10. The stock’s 50 day moving average price is $15.42 and its two-hundred day moving average price is $16.91.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. Equities research analysts expect that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 7.26%. Organon & Co.’s dividend payout ratio is currently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.